Results 1 to 10 of about 411,227 (332)

Antibody Engineering at the Millennium [PDF]

open access: goldBioTechniques, 2000
It has been almost 100 years since von Behring and Kitasato received the first Nobel prize for the discovery of passive immunotherapy and nearly 25 years since Köhler and Milstein first reported hybridoma technology. In the 15 years since Mullis and co-workers described PCR, a number of discoveries and technologies have converged to produce a ...
James W Larrick, Jorge V. Gavilondo
openaire   +5 more sources

IgG Fc engineering to modulate antibody effector functions [PDF]

open access: diamondProtein & Cell, 2017
Therapeutic monoclonal antibodies are among the most effective biotherapeutics to date. An important aspect of antibodies is their ability to bind antigen while at the same time recruit immune effector functions.
Xinhua Wang   +2 more
doaj   +2 more sources

i-shaped antibody engineering enables conformational tuning of biotherapeutic receptor agonists [PDF]

open access: yesNature Communications
The ability to leverage antibodies to agonize disease relevant biological pathways has tremendous potential for clinical investigation. Yet while antibodies have been successful as antagonists, immune mediators, and targeting agents, they are not readily
Matthew G. Romei   +16 more
doaj   +2 more sources

Antibody Engineering for Pursuing a Healthier Future. [PDF]

open access: yesFront Microbiol, 2017
Since the development of antibody-production techniques, a number of immunoglobulins have been developed on a large scale using conventional methods. Hybridoma technology opened a new horizon in the production of antibodies against target antigens of ...
Saeed AF, Wang R, Ling S, Wang S.
europepmc   +2 more sources

mCSM-AB: a web server for predicting antibody-antigen affinity changes upon mutation with graph-based signatures. [PDF]

open access: yes, 2016
Computational methods have traditionally struggled to predict the effect of mutations in antibody-antigen complexes on binding affinity. This has limited their usefulness during antibody engineering and development, and their ability to predict ...
Ascher, David B, Pires, Douglas EV
core   +15 more sources

A seroepidemiological survey of adenovirus type 7 circulation among healthy adults in China and in Sierra Leone, West Africa

open access: yesFrontiers in Public Health, 2023
Adenovirus type 7 (HAdV7) is one of the most pathogenic human adenoviruses (HAdVs) and can cause severe illness and even death, particularly in people with weakened immune systems.
Busen Wang   +12 more
doaj   +1 more source

Screening of potential vaccine candidates against pathogenic Brucella spp. using compositive reverse vaccinology

open access: yesVeterinary Research, 2021
Brucella spp. are Gram-negative, facultative intracellular bacteria that cause brucellosis in humans and various animals. The threat of brucellosis has increased, yet currently available live attenuated vaccines still have drawbacks.
Xiaodong Zai   +8 more
doaj   +1 more source

A Bivalent COVID-19 Vaccine Based on Alpha and Beta Variants Elicits Potent and Broad Immune Responses in Mice against SARS-CoV-2 Variants

open access: yesVaccines, 2022
With the emergence and rapid spread of new pandemic variants, especially variants of concern (VOCs), the development of next-generation vaccines with broad-spectrum neutralizing activities is of great importance.
Rui Wang   +19 more
doaj   +1 more source

A novel Galleria mellonella experimental model for zoonotic pathogen Brucella

open access: yesVirulence, 2023
Brucellosis is a major threat to public health and animal husbandry. Several in vivo vertebrate models, such as mice, guinea pigs, and nonhuman primates, have been used to study Brucella pathogenesis, bacteria-host interactions, and vaccine efficacy ...
Shuyi Wang   +11 more
doaj   +1 more source

Home - About - Disclaimer - Privacy